WHO naming stem · suffix · 34 listed names
-lisib
This page was written with AI.
phosphatidylinositol 3-kinase inhibitors, antineoplastics
Where it sits in a name
WHO writes the stem as -lisib. So the letters lisib sit at the end of the name (…lisib).
All 34 names WHO lists under -lisib
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 8 of 34 names appear in these lists: 8 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- acalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- alpelisib
- amdizalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- apitolisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- bimiralisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- buparlisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- copanlisibEU (central) brands: none found
- dactolisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- dezapelisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- duvelisibUS brands: COPIKTRA
- eganelisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- gedatolisibUS brands: REVTORPYKEU (central) brands: none found
- gilmelisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- idelalisibUS brands: ZYDELIGEU (central) brands: Zydelig
- inavolisibUS brands: ITOVEBIEU (central) brands: Itovebi
- izorlisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- leniolisibUS brands: JOENJAEU (central) brands: Joenja
- linperlisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- nemiralisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- omipalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- panulisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- parsaclisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- paxalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pictilisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pilaralisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- recilisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- risovalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- samotolisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- seletalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- serabelisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tenalisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- umbralisibEU (central) brands: none found
- vulolisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- zandelisibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Decode another name
Decoded
acalisib
Listed INNCarries the WHO stem -lisib
- -lisibend of the nameWHO lists it hereWHO definition: phosphatidylinositol 3-kinase inhibitors, antineoplastics
“acalisib” is an INN that WHO lists under -lisib in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -lisib (Part II B) and the 34 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.